EGFR and intrahepatic cholangiocarcinoma: As advanced NSCLC patients without mutations in EGFR/BRAF or EML4‐ALK/ROS1 fusions are amenable to single anti‐PD‐1 therapy, that is, pembrolizumab or in combination with chemotherapy, the PD‐L1 expression was also analyzed in a subset of the cases (by IHC: #3, #6, #11, #15; #19, #20, #26, and by ICC: #22, #23; #24) (Table 1).